Clear Street Maintains Buy on Nuvation Bio Despite Pipeline Adjustment
Clear Street keeps $12 price target on NUVB after NUV-1511 discontinuation, citing blockbuster potential for IBTROZI and safusidenib programs.
/ 913 items
#Healthcare↓
Piper Sandler Upgrades Oscar Health to Overweight, Sees Strong Profit Potential
Piper Sandler upgrades Oscar Health to Overweight with a $25 price target, citing growth and profitability potential through 2027.
FDA Grants Priority Review to BeOne’s New Drug for Aggressive Blood Cancer
The FDA has accepted and fast-tracked BeOne Medicines’ new drug sonrotoclax for adults with relapsed or refractory mantle cell lymphoma, a rare and fast-growing blood cancer.
UBS Downgrades Biohaven on Pipeline Setbacks
UBS cuts Biohaven to Neutral from Buy, lowering the price target to $11 due to multiple R&D and regulatory setbacks and rising competition in its Kv7 program.
LIXTE Biotechnology Steps into Next-Gen Cancer Treatment with Liora Acquisition
LIXTE Biotechnology bought Liora Technologies to get the LiGHT System, a cutting-edge, high-precision proton therapy for cancer treatment.
UK NICE Approves AUCATZYL CAR T Therapy for Adult B-ALL Patients
NICE recommends Autolus AUCATZYL (obecabtagene autoleucel) for adults 26+ with relapsed/refractory B-cell acute lymphoblastic leukemia in England and Wales.